pub med big

Anticancer mechanisms of cannabinoids.

  Journal List > Curr Oncol > v.23(Suppl 2); 2016 Mar > PMC4791144 Curr Oncol. 2016 Mar; 23(Suppl 2): S23–S32.  Published online 2016 Mar 16. doi:  10.3747/co.23.3080 PMCID: PMC4791144 Anticancer mechanisms of cannabinoids G. Velasco, PhD,*†‡ C. Sánchez, PhD,*§ and  M. Guzmán, PhD*†‖ Author information ► Copyright and License information ► Go to: Abstract In addition to the well-known palliative effects of cannabinoids on some cancer-associated symptoms, a large body […]

PM 2 site 207

Marijuana’s Effects on Brain Structure and Function: What Do We Know and What Should We Do? A Brief Review and Commentary.

Am J Med. 2018 Sep 18. pii: S0002-9343(18)30872-6. doi: 10.1016/j.amjmed.2018.09.006. [Epub ahead of print] deShazo RD1, Parker SB2, Williams D3, Ingram JB4, Elsohly M5, Rodenmeyer K5, McCullouch K6. Author information Abstract The recent Federal Drug Administration approval of the marijuana constituent cannabidiol (CBD) as safe and effective for treatment of two rare forms of epilepsy, […]

PM 2 site 207

Cannabinoid WIN 55,212-2 induces cell cycle arrest and apoptosis, and inhibits proliferation, migration, invasion, and tumor growth in prostate cancer in a cannabinoid-receptor 2 dependent manner.

Prostate. 2018 Sep 21. doi: 10.1002/pros.23720. [Epub ahead of print] Roberto D1,2, Klotz LH1,2, Venkateswaran V1,2. Author information Abstract BACKGROUND: Cannabinoids have demonstrated anticarcinogenic properties in a variety of malignancies, including in prostate cancer. In the present study, we explored the anti-cancer effects of the synthetic cannabinoid WIN 55,212-2 (WIN) in prostate cancer. METHODS: Established […]

PM 2 site 207

Cannabidiol modulation of antinociceptive tolerance to Δ9-tetrahydrocannabinol.

Psychopharmacology (Berl). 2018 Sep 20. doi: 10.1007/s00213-018-5036-z. [Epub ahead of print] Greene NZ1, Wiley JL2, Yu Z3, Clowers BH3, Craft RM4. Author information Abstract RATIONALE: Humans typically self-administer cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC) together repeatedly (as in cannabis, cannabis extract, or Sativex®) to relieve pain. It has been suggested that one benefit of the drug […]

PM 2 site 207

Acceptance of pharmaceutical cannabis substitution by cannabis using patients with schizophrenia.

Harm Reduct J. 2018 Sep 20;15(1):47. doi: 10.1186/s12954-018-0253-7. van Amsterdam J1, Vervloet J2, de Weert G2, Buwalda VJA2, Goudriaan AE3,2, van den Brink W3. Author information Abstract BACKGROUND: Cannabis-smoking patients with a psychotic disorder have poorer disease outcomes than non-cannabis-smoking patients with poorest outcomes in patients smoking high-potency cannabis (HPC) containing high Δ9-tetrahydrocannabinol (THC) and […]

PM 2 site 207

A review of the effects of baclofen and of THC:CBD oromucosal spray on spasticity-related walking impairment in multiple sclerosis.

Expert Rev Neurother. 2018 Sep 20:1-7. doi: 10.1080/14737175.2018.1510772. [Epub ahead of print] Arroyo González R1. Author information Abstract Multiple sclerosis (MS) is a complex disease with a heterogeneous and unpredictable clinical course. Mobility impairment after progressive paralyses and muscle tone spasticity is common. Areas covered: The prevalence, assessment, and pharmacological management of gait impairment and […]

PM 2 site 207

Combined CB2 Receptor Agonist and Photodynamic Therapy Synergistically Inhibit Tumor Growth in Triple Negative Breast Cancer.

Photodiagnosis Photodyn Ther. 2018 Sep 18. pii: S1572-1000(18)30157-1. doi: 10.1016/j.pdpdt.2018.09.006. [Epub ahead of print] Zhang J1, Zhang S2, Liu Y3, Su M3, Ling X2, Liu F4, Ge Y1, Bai M5. Author information Abstract Triple negative breast cancer (TNBC) is the deadliest form of breast cancer because compared with other types of breast cancer, it is […]

PM 2 site 207

Effect of cannabidiolic acid and ∆9-tetrahydrocannabinol on carrageenan-induced hyperalgesia and edema in a rodent model of inflammatory pain.

Psychopharmacology (Berl). 2018 Sep 17. doi: 10.1007/s00213-018-5034-1. [Epub ahead of print] Rock EM1, Limebeer CL1, Parker LA2. Author information Abstract RATIONALE: Cannabidiol (CBD), a non-intoxicating component of cannabis, or the psychoactive Δ9-tetrahydrocannabiol (THC), shows anti-hyperalgesia and anti-inflammatory properties. OBJECTIVES: The present study evaluates the anti-inflammatory and anti-hyperalgesia effects of CBD’s potent acidic precursor, cannabidiolic acid […]

PM 2 site 207

Cannabidiol enhances morphine antinociception, diminishes NMDA-mediated seizures and reduces stroke damage via the sigma 1 receptor.

Mol Brain. 2018 Sep 17;11(1):51. doi: 10.1186/s13041-018-0395-2. Rodríguez-Muñoz M1, Onetti Y1, Cortés-Montero E1, Garzón J1, Sánchez-Blázquez P2. Author information Abstract Cannabidiol (CBD), the major non-psychotomimetic compound present in the Cannabis sativa plant, exhibits therapeutic potential for various human diseases, including chronic neurodegenerative diseases, such as Alzheimer’s and Parkinson’s, ischemic stroke, epilepsy and other convulsive syndromes, […]

PM 2 site 207

A missed opportunity? Cannabis legalization and reparations in Canada.

Can J Public Health. 2018 Sep 17. doi: 10.17269/s41997-018-0121-y. [Epub ahead of print] Valleriani J1,2, Lavalley J3, McNeil R3,4. Author information Abstract As Canada moves towards the legalization of cannabis, the Cannabis Act itself remains void of any complementary social justice measures. Decades of criminalization for the possession, production, and sale of cannabis will remain […]

PM 2 site 207

Inflammation and CB2 signaling drive novel changes in the ocular lipidome and regulate immune cell activity in the eye.

Prostaglandins Other Lipid Mediat. 2018 Sep 16. pii: S1098-8823(18)30025-X. doi: 10.1016/j.prostaglandins.2018.09.004. [Epub ahead of print] Toguri JT1, Leishman E2, Szczesniak AM1, Laprairie RB3, Oehler O2, Straiker AJ2, Kelly M4, Bradshaw HB5. Author information Abstract Uveitis is inflammation of the uvea which consists of the iris, ciliary body and the choroid of the eye. Uveitis can […]